FindTrial
Sign In

Bevacizumab Biosimilar IBI305

DRUG5 trials

Sponsors

Tongji Hospital, The First Affiliated Hospital with Nanjing Medical University, Tianjin Medical University Cancer Institute and Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Conditions

Conversion TherapyHCC - Hepatocellular CarcinomaHepatocellular CarcinomaHepatocellular Carcinoma RecurrentNon Small Cell Lung CancerOvarian Clear Cell CarcinomaPost-orthotopic Liver Transplantation

Phase 2

Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma
CompletedNCT04735861
Tongji HospitalOvarian Clear Cell Carcinoma
Start: 2021-04-07End: 2024-07-30Updated: 2024-08-13
Bevacizumab Biosimilar Plus FOLFOX4 in the Treatment of Recurrent HCC After Liver Transplantation
NCT05355155
The First Affiliated Hospital with Nanjing Medical UniversityHepatocellular Carcinoma Recurrent, Post-orthotopic Liver Transplantation
Start: 2022-05-01End: 2024-12-31Target: 15Updated: 2022-05-11
Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations
NCT05507606
Tianjin Medical University Cancer Institute and HospitalNon Small Cell Lung Cancer
Start: 2021-08-01End: 2024-08-01Target: 50Updated: 2022-08-19
Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma
NCT05617430
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyHepatocellular Carcinoma
Start: 2022-11-02End: 2024-06-30Target: 43Updated: 2022-11-15
Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma
RecruitingNCT07560488
Tianjin Medical University Cancer Institute and HospitalConversion Therapy, HCC - Hepatocellular Carcinoma
Start: 2026-03-30End: 2028-04-01Target: 43Updated: 2026-05-01

Related Papers

Osimertinib combined with bevacizumab and chemotherapy as 1L treatment in EGFR-mutated metastatic non-squamous non-small cell lung cancer (nsq NSCLC) with concurrent mutations.
Journal of Clinical Oncology2026-05-28
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial.
2024-09-1116 citations
Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial—a study protocol of clinical trial
BMJ Open2022-05-0110 citations